company background image
IMUX

ImmunicNasdaqGS:IMUX Stock Report

Market Cap

US$218.4m

7D

-3.4%

1Y

-54.1%

Updated

04 Dec, 2021

Data

Company Financials +
IMUX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IMUX Stock Overview

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Immunic
Historical stock prices
Current Share PriceUS$8.32
52 Week HighUS$28.21
52 Week LowUS$6.96
Beta1.9
1 Month Change-16.72%
3 Month Change-17.62%
1 Year Change-54.14%
3 Year Changen/a
5 Year Changen/a
Change since IPO-65.51%

Recent News & Updates

Aug 13
Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

IMUXUS BiotechsUS Market
7D-3.4%-4.1%-2.7%
1Y-54.1%-1.4%16.6%

Return vs Industry: IMUX underperformed the US Biotechs industry which returned -1.4% over the past year.

Return vs Market: IMUX underperformed the US Market which returned 16.6% over the past year.

Price Volatility

Is IMUX's price volatile compared to industry and market?
IMUX volatility
IMUX Average Weekly Movement7.5%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: IMUX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: IMUX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a52Daniel Vitthttps://www.immunic-therapeutics.com

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR

Immunic Fundamentals Summary

How do Immunic's earnings and revenue compare to its market cap?
IMUX fundamental statistics
Market CapUS$218.40m
Earnings (TTM)-US$82.92m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMUX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$82.92m
Earnings-US$82.92m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.16
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IMUX perform over the long term?

See historical performance and comparison

Valuation

Is Immunic undervalued compared to its fair value and its price relative to the market?

1.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMUX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IMUX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMUX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMUX is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (2.6x).


Future Growth

How is Immunic forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

20.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMUX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMUX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMUX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMUX is forecast to have no revenue next year.

High Growth Revenue: IMUX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMUX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Immunic performed over the past 5 years?

-49.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMUX is currently unprofitable.

Growing Profit Margin: IMUX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMUX is unprofitable, and losses have increased over the past 5 years at a rate of 49.1% per year.

Accelerating Growth: Unable to compare IMUX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMUX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: IMUX has a negative Return on Equity (-57%), as it is currently unprofitable.


Financial Health

How is Immunic's financial position?


Financial Position Analysis

Short Term Liabilities: IMUX's short term assets ($122.5M) exceed its short term liabilities ($10.6M).

Long Term Liabilities: IMUX's short term assets ($122.5M) exceed its long term liabilities ($701.0K).


Debt to Equity History and Analysis

Debt Level: IMUX is debt free.

Reducing Debt: IMUX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMUX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMUX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 47.2% each year.


Dividend

What is Immunic current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMUX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMUX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMUX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMUX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMUX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Daniel Vitt (53 yo)

2.67yrs

Tenure

US$1,318,054

Compensation

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic AG since April 2019 and also its President. Dr. Vitt served as Managing Director of 4SC Discovery GmbH. Dr. Vitt Co-founded 4SC AG in No...


CEO Compensation Analysis

Compensation vs Market: Daniel's total compensation ($USD1.32M) is about average for companies of similar size in the US market ($USD1.15M).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IMUX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: IMUX's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.7%.


Top Shareholders

Company Information

Immunic, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Immunic, Inc.
  • Ticker: IMUX
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$218.395m
  • Shares outstanding: 26.25m
  • Website: https://www.immunic-therapeutics.com

Number of Employees


Location

  • Immunic, Inc.
  • 1200 Avenue of the Americas
  • Suite 200
  • New York
  • New York
  • 10036
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 00:16
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.